SCHEMBL855754

SCHEMBL855754

CC(C)Oc1ccccc1CN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.47
CSNK2A1 P68400 2/20 0.44
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
KCNH2 Q12809 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42
ALDH1A1 P00352 1/20 0.41
ACHE P22303 1/20 0.41
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
PNMT P11086 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TLR8 Q9NR97 1/20 0.40
MCHR1 Q99705 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29786441 1.00 IRAK4 (0.47) IRAK4CSNK2A1SLC6A2SLC6A4KCNH2
SCHEMBL3842137 0.84 TAAR1 (0.63) IRAK4SLC6A2SLC6A4KCNH2TAAR1
SCHEMBL7013166 0.82 MCHR1 (0.46) TAAR1ALDH1A1PNMTMCHR1
SCHEMBL8254794 0.82 MCHR1 (0.44) KCNH2TAAR1ALDH1A1PNMTMCHR1
SCHEMBL1470815 0.81 TAAR1 (0.50) IRAK4SLC6A2SLC6A4KCNH2TAAR1
SCHEMBL14047087 0.81 TAAR1 (0.38) IRAK4TAAR1ALDH1A1PNMTSMN1; SMN2
SCHEMBL8796327 0.81 TAAR1 (0.38) IRAK4TAAR1PNMTSMN1; SMN2
SCHEMBL22397181 0.81 TAAR1 (0.38) IRAK4TAAR1PNMTSMN1; SMN2
SCHEMBL694395 0.81 SLC6A2 (0.44) IRAK4SLC6A2SLC6A4KCNH2ALDH1A1
SCHEMBL5412735 0.81 ADRA2A (0.51) IRAK4SLC6A2SLC6A4KCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0984967-B1 NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS IAF BIOCHEM INT (CA) 2004-02-25 EP claimed
EP-1037633-B1 ANTIVIRAL COMPOUNDS IAF BIOCHEM INT (CA) 2003-09-10 EP claimed
EP-1155017-B1 [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY SHIRE BIOCHEM INC (CA) 2003-01-15 EP claimed
US-20010031765-A1 Antiviral compounds BIOCHEM PHARMA INC. 2001-10-18 US claimed
CN-1283995-A Antiviral compounds IAF BIOCHEM INT (CA) 2001-02-14 CN claimed
EP-1037633-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC (CA) 2000-09-27 EP claimed
WO-1999029318-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC. (CA) 1999-06-17 WO claimed
US-20250074909-A1 AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2025-03-06 US disclosed
US-12157733-B2 Aminotriazolopyridines as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-12-03 US disclosed
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 TRANSLATIONAL GENOMICS RES INST (US) 2023-11-02 US disclosed
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 TRANSLATIONAL GENOMICS RES INST (US) 2023-11-02 US disclosed
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 TRANSLATIONAL GENOMICS RES INST (US) 2023-11-02 US disclosed
US-20220315580-A1 AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2022-10-06 US disclosed
CN-1283995-A Antiviral compounds IAF BIOCHEM INT (CA) 2001-02-14 CN disclosed
EP-1037633-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC (CA) 2000-09-27 EP disclosed
EP-0984967-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS BIOCHEM PHARMA INC (CA) 2000-03-15 EP disclosed
US-5945431-A VIRICIDE BIOCHEM THERAPEUTICS INCORPORATED (CA) 1999-08-31 US disclosed
WO-1999029318-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC. (CA) 1999-06-17 WO disclosed
CN-1218473-A Naphthyridine derivatives and their analogues inhibiting cytomegalovirus IAF BIOCHEM INT (CA) 1999-06-02 CN disclosed
WO-1997034894-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS BIOCHEM PHARMA INC. (CA) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074909-A1 AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 IRAK4 112/4885CSNK2A1 472/4885SLC6A2 4236/4885
US-20230348475-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 CDK7, CDK8, CDKL4 IRAK4 629/4885CSNK2A1 72/4885SLC6A2 4196/4885
US-20220315580-A1 AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 IRAK4 112/4885CSNK2A1 472/4885SLC6A2 4236/4885
US-12157733-B2 Aminotriazolopyridines as kinase inhibitors RIPK1, RIPK3, RIPK4 IRAK4 112/4885CSNK2A1 472/4885SLC6A2 4236/4885
US-20010031765-A1 Antiviral compounds ZC3HAV1, IFNAR1, EIF2AK2 IRAK4 953/4885CSNK2A1 2361/4885SLC6A2 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.